Intellia Therapeutics, Inc. (NTLA) is listed on NasdaqGM in the Healthcare sector Β· Biotechnology industry. The current price is 12.65, down -0.82% from the previous close. Market cap is approximately $1.8B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
A low ROE of -55.44% is common in capital-heavy sectors (utilities, heavy industry, infrastructure) or after large equity raises.
Intellia Therapeutics, Inc.'s elevated D/E of 10.09 either reflects an aggressive growth-via-debt strategy or balance sheet stress. Operating cash flow trend is the cleanest tell.
Intellia Therapeutics, Inc.'s revenue growth of -46.20% is negative. Worth breaking down whether the drop is price (ASP) or volume in IR materials.
Demographic-driven structural demand growth is a long-running tailwind for healthcare.
Intellia Therapeutics, Inc. sits in the lower 23% of its 52-week range (7.95β28.25). The stock has pulled back from its highs; whether that reflects sector-wide conditions or a company-specific issue is the first thing to establish.
The day's high-to-low spread reached 4.19%, with a -0.82% move. Wide sessions frequently follow earnings, filings, or sector news, so identifying the catalyst matters.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
Intellia Therapeutics, Inc. (NTLA) is listed on NasdaqGM, with recent volume of 1,480,085 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.